The global market for drug-eluting stents had a valuation of $105.6 million in 2022, and it is projected to grow at a CAGR of 1.8% during the forecast period, reaching $119.6 million. The comprehensive report on the market focuses solely on drug-eluting stents and does not include its extended set.
Intersect ENT dominates the drug-eluting stent market with its Propel® family of products. These stents are designed to be used in combination with ethmoid sinus surgery, with different shapes and sizes available to suit different sinus anatomies. The company's product line also includes Sinuva® Sinus Implant, which is used to treat nasal polyps in patients who have undergone previous ethmoid sinus surgery. Both Propel® and Sinuva® implants release the corticosteroid mometasone furoate.
MARKET DATA INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- COVID-19 Impact Analysis
- Market Drivers & Limiters
- Market Forecasts Until 2029, and Historical Data to 2019
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
GLOBAL DRUG-ELUTING STENT MARKET INSIGHTS
The primary driver of the drug-eluting stent market is the lack of competition. Intersect ENT is the sole competitor in the market, which enables the company to maintain higher selling prices, driving up the market value. The company's monopoly on the market is a significant factor in the growth of the drug-eluting stent market.GLOBAL DRUG-ELUTING STENT MARKET SHARE INSIGHTS
The Global drug-eluting stent market was led by Intersect ENT.Intersect ENT dominates the drug-eluting stent market with its Propel® family of products. These stents are designed to be used in combination with ethmoid sinus surgery, with different shapes and sizes available to suit different sinus anatomies. The company's product line also includes Sinuva® Sinus Implant, which is used to treat nasal polyps in patients who have undergone previous ethmoid sinus surgery. Both Propel® and Sinuva® implants release the corticosteroid mometasone furoate.
MARKET SEGMENTATION SUMMARY
- ENT Drug-Eluting Stent Market - MedCore
RESEARCH SCOPE SUMMARY
- Regions: North America (Canada, United States), Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela), Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.), Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine), Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates), Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam), Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda)
- Base Year: 2022
- Forecast Period: 2023-2029
- Historical Data: 2019-2022
- Quantitative Data: Market Size, Market Share, Market Growth Rates, Units Sold, Average Selling Prices
- Qualitative Data: COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios
- Data Sources: Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data.
Table of Contents
Drug-Eluting Stent Market- Introduction
- Market Analysis and Forecast
- Drivers and Limiters
- Market Drivers
- Market Limiters
- Competitive Market Share Analysis
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Intersect ENT
